

Hydroxurea treatment in sickle cell children

Marie-Hélène Odièvre^{1,4}, Malika Benkerrou², Marie Belloy³, Jacques Elion¹

¹Inserm, UMR 763, Paris, F-75019 France ; Université Paris Diderot, Paris, France

²AP-HP, Hop Robert-Debré, Centre de la Drépanocytose, Paris, F-75019 France

³Hop de Gonesse, Service de Pédiatrie, Gonesse, F-95500 France

⁴AP-HP, Hop Louis-Mourier, Service de Pédiatrie, Colombes, F-92700 France

Corresponding author

Jacques Elion, Inserm U763, Hôpital Robert Debré, 48 Bd Sérurier, 75019 Paris, France. Email : jacques.elion@inserm.fr

Sickle cell anaemia, the most prevalent genetic disease in the black population, is characterised by the polymerisation of the abnormal haemoglobin S, which leads to vascular occlusion and severe painful crisis. Hydroxyurea is the first drug that has been shown to reduce the clinical severity of sickle cell anaemia in adults. Several trials have been carried out in more than 400 children in the last decade, using different therapeutic schedules. Enrolment was based on clinical vasoocclusive severity and few studies included children with cerebrovascular events. Hydroxyurea enhanced fetal haemoglobin expression in almost all the children, despite a large inter-

individual variability. Hydroxyurea significantly reduces the number of vasoocclusive crises, hospitalisations, the frequency of the acute chest syndrome and the rate of transfusion. Long-term tolerance to hydroxyurea is good. However, clinical response does not correlate consistently with the degree and with the time of increment in fetal haemoglobin, suggesting that hydroxyurea may mediate some of its clinical benefits through other mechanisms such as the reduction of sickle erythrocytes – endothelial cells adherence and of the vasoconstrictive stimulus.

Paed Perinat Drug Ther 2008; 8: 158–170

Keywords: sickle cell anaemia – hydroxurea – fetal haemoglobin – endothelium – child – review

Introduction

Sickle cell anaemia (SCA) is the most prevalent hereditary disorder in black individuals. It was first described in 1910, when the abnormal red cell shape named “sickle cell” was recognised¹. Identification of the abnormal haemoglobin (HbS) in 1949 made it the first described molecular disease² leading to the definition of a precise pathophysiological scheme in the early 1960s. Despite these biological progresses, advances in therapy remain modest contrasting with the large prevalence of the disease

particularly among black people. The basic pathophysiological scheme is the abnormal tendency of HbS to polymerise under hypoxic conditions with resulting sickling. This scheme explains chronic haemolytic anaemia, episodic occurrence of painful crises believed to result from vascular occlusion by undeformable rigid sickle cells inside the microvasculature leading to tissue ischaemia, and infectious complications. However, this mechanism is proving insufficient as laboratory data point out that the time necessary for developing cell sickling is longer than the microvascular transit time³.

Recent evidence supports the hypothesis that abnormal adhesiveness of erythrocytes from SCA patients to vascular endothelial cells increases the transit times through small vessels and precipitates the occurrence of vasoocclusive crises (VOC)⁴. This observation makes red cell-endothelial cell interactions a central point of the pathophysiological scheme⁵.

When present in the erythrocyte, fetal haemoglobin (HbF) inhibits deoxy-HbS polymerisation and hydroxyurea (HU, also referred to as hydroxycarbamide) treatment was initially given to reinduce HbF expression. In 1995, a large clinical trial in adults ($n=299$) with a history of at least three VOC per year showed that HU therapy caused a significant reduction in the frequency of painful crises, the frequency of acute chest syndrome (ACS) and the number of transfusions⁶. Others confirmed that adult patients taking HU for severe VOC had reduced mortality after nine years follow up⁷. Since 1996, studies have not involved randomisation because of the proven efficacy of HU therapy. Marketing authorisation of HU for use in adult SCA patients was awarded in the United States of America (USA) in 1998 (Droxia®) and authorisation for use in adult and children with SCA was awarded in the European Union in 2007 (Siklos®).

Paediatric trials

Between 1996 and 2006, data from more than 400 paediatric patients treated with HU for a severe clinical course of SCA have been published⁸⁻³¹ (Table 1). The majority were conducted in the USA^{8,10,13,15,17-19,22-24,26-28,31}. There have also been studies in Belgium^{9,14,21,29}, France^{11,12,20,30}, Israel¹⁶ and Brazil²⁵. Most children were SS homozygotes but 46 were S/β thal compound heterozygotes^{8,11-14,16,20,23,25,27-31}, five were S/O Arab compound heterozygotes^{13,17,27,28}, three had S/D Punjab compound heterozygosity^{21,29,30}; one study included only severely affected S/C children²².

Most trials involved < 40 children, but four studies included 84–225 children^{18,20,21,29,30}. The French study has been both the largest and had the longest follow up^{11,12,20,30}. The mean age of patients ranged from 9 to 15.3 years in the majority of the studies; however, several studies have involved young children under the age of 5 years^{19,21,23,25,27-31}. One study has 14 children younger than two years with a minimum follow up of two years of HU therapy²⁹.

Clinical indication

In the majority of studies, enrolment (Table 1) was made on the basis of clinical evidence of

disease severity^{8,11-13,15,16,18-20,22,24-27,29,30}; usually three or more severe VOC during the last year and/or two or more ACS requiring hospitalisation during the last two years, and/or priapism. Two studies^{17,28} included only patients with cerebrovascular events while five other studies^{9,21,27,29,30} added aseptic hip necrosis and/or history of splenic sequestration and/or cerebrovascular event or abnormal transcranial doppler (TCD) and/or cardiac ischaemia to the VOC. Severe anaemia with haemoglobin (Hb) levels less than 7.0 g/dl^{10,30} and/or requiring more than one transfusion per month to maintain haemoglobin level over 8.0 g/dl¹⁴ was also an indication for treatment. The 28 very young patients treated in two studies^{23,31} were not selected on the basis of disease severity but to test the potential for HU to preserve organ function, principally splenic function.

Dosage

The treatment schedule varied largely from one study to the other (Table 1). The initial daily dose (7 to 20 mg/kg) was usually systematically increased by 5 mg/kg every eight weeks until the maximum tolerated dose (MTD) avoiding bone marrow toxicity^{8,10,13-15,17-19,22,24-28} was reached. The HU dose to reach MTD ranged from 15 to 35 mg/kg. In the "HUG-KIDS Study"¹⁸, HU was discontinued for a least one week when the patient experienced a haematological toxicity; once the toxicity resolved, HU was restarted at a dose 2.5 mg/kg lower than the dose at which the toxicity occurred and was subsequently increased by 2.5 mg/kg every eight weeks, provided toxicity did not occur. In this study, MTD was defined as the dose 2.5 mg/kg below which two successive haematological toxicities occurred or when the daily dose reached 30 mg/kg and was sustained without toxicity for eight weeks.

For their very young children, Wang et al.²³ used a fixed dose of 20 mg/kg/day, adjusted for weight every eight weeks. In other studies, the daily maintenance dose was planned between 25 and 35 mg/kg^{9,16,20,21,23,29,31} or 40 mg/kg four days a week (i.e. 20-23 mg/kg/day) in the French studies^{11,12,30}. In their pilot study, Ferster et al.⁹ used an initial daily dose of 20 mg/kg increased to 25 mg/kg if no change in HbF level had occurred after two months (increase < 2%). Their patients were randomly allocated to the sequence HU for six months followed by placebo for six months, or placebo followed by HU for an additional six months. It should be stressed that this is the only randomised paediatric study even though, in retrospect, the six month crossover period can be questioned as it is now established that the HbF level can increase up to 12 months after the onset of HU therapy. Another schedule was used by

Table 1 Different paediatric trials

Ref.	State	Number of patients	Ages of patients (years)	Phenotype	Enrolment	Maximum tolerated dose (mg)	Usual maintenance dose (mg/kg/day)
8	United States	15	Mean 14 Range 10–17	SS: <i>n</i> =11 Sβ ⁰ : <i>n</i> =2 SS + α thal: <i>n</i> =2	VOC, ACS, priapism	Yes	Mean 21.4 ± 5.2 Range 14–34.7
9	Belgium	25	Mean 9 Median 8 Range 9–22	SS SS + α thal	VOC, ACS, stroke Splenic sequestration	No Max 25	Range 20–25
10	United States	15	Median 15.3 Range 4.4–18.8	SS	VOC, ACS, low Hb	Yes Max 35	Median 25.9
11	France	35	Mean 10.9 ± 4.1	SS: <i>n</i> =33	VOC	No Max 40	Mean 34.2 ± 4.6
12			Median 11.4 Range 4–19	Sβ ⁰ : <i>n</i> =1 Sβ ⁺ : <i>n</i> =1			
13	United States	16	Median 14.2 Range 5.3–18.4	SS: <i>n</i> =13 Sβ ⁰ : <i>n</i> =1 Sβ ⁺ : <i>n</i> =1 SOArab: <i>n</i> =1	VOC, ACS, priapism	Yes	35
14	Belgium	8	Range 5–16	SS: <i>n</i> =6 Sβ: <i>n</i> =2	VOC, low Hb	Yes	Range 14–27
15	Canada + United States	17	Mean 12.4 ± 1.2 Range 5.2–18		VOC, ACS	Yes	Mean 21.8 ± 2.8 Range 6.7–32
16	Israel	19	Mean 15.1 ± 4 Range 7–23	SS: <i>n</i> =9 Sβ ⁰ : <i>n</i> =9 Sβ ⁺ : <i>n</i> =1	VOC, ACS Stroke (<i>n</i> =1) Hypersplenism (<i>n</i> =1)	No	Mean 21.3 ± 4.9 Range 16.4–31.2
17	United States	16	Mean 7.1 ± 4.4 Median 6.4	SS: <i>n</i> =15 SOArab: <i>n</i> =1	Stroke	Yes or Max 30 overlap with transfusion: none	Mean 24.9 ± 4.2 Range 19.1–32.7
18	United States “HUG-KIDS Study”	84	Mean 9.8 ± 3.2 Median 9.1 Range 5–15	SS: <i>n</i> =83 ?: <i>n</i> =1	VOC, ACS	Yes or Max 30	Mean 25.6 ± 6.2 Range 7.5–30
19	United States	8	Mean 3.7 Median 3.7 Range 2–5	SS	VOC, ACS	Yes or Max 30	Mean 27 ± 4
20	France	101	Mean 9.8 ± 0.4 Range 2–20	SS: <i>n</i> =99 Sβ ⁰ : <i>n</i> =1 Sβ ⁺ : <i>n</i> =1	VOC	No	Mean 21.4 ± 0.5 Range 9–30
21	Belgium	93	Median 7 Range 0.67–45	SS: <i>n</i> =92 SDPunjab: <i>n</i> =1	VOC, ACS, priapism Stroke Ischaemic bone necrosis Splenic sequestration (<i>n</i> =1)	No	Range 20–30
22	United States	6	Range 6.7–17.5	SC	VOC, ACS	Yes or Max 30	Median 1000 mg/day Range 750–1600 mg/day
23	United States	28	Median 15 month Range 6–28 m	SS: <i>n</i> =27 Sβ ⁰ : <i>n</i> =1	Not on the basis of the disease severity	No Fixed dose 20	
24	United States	5	Range 11–14	SS	VOC, ACS	Yes Max 30	Mean 27 Range 20–30
25	Brazil	21	Mean 11.7 Range 3–22	SS: <i>n</i> =14 Sβ ⁰ : <i>n</i> =7	VOC, ACS, priapism	Yes Max 30	
26	United States “HUG-KIDS Study”	68 achieved MTD 84 enrolled	Mean 9.5	SS	VOC, ACS	Yes or Max 30	
27	United States “HUG-KIDS Study” and “HUSOFT trial” and other studies	122	Median 11.1 Range 0.5–19.7	SS: <i>n</i> =106 SC: <i>n</i> =7 Sβ ⁰ : <i>n</i> =6 Sβ ⁺ : <i>n</i> =1 SOArab: <i>n</i> =2	VOC, ACS Stroke	Yes or Max 30–35	Mean 25.4 ± 5.4
28	United States	35	Mean 11.9 ± 4 Range 3.0–19.9	SS: <i>n</i> =33 Sβ ⁰ : <i>n</i> =1 SOArab: <i>n</i> =1	Stroke	Yes overlap with transfusion: 6 ± 3 months	Mean 26.7 ± 4.8 Range 17–34.8
29	Belgium	127	Median 6 Range 0.67–19	SS: <i>n</i> =119 Sβ ⁰ : <i>n</i> =4 SC: <i>n</i> =3 SDPunjab: <i>n</i> =1	VOC, ACS, priapism Stroke Abnormal transcranial doppler Ischaemic bone necrosis	No	After 1 year of treatment 49% patients: mean <20 46% patients: mean 20–25 1.9% patients: mean 25–30 0.9% patients: mean >30
30	France	225	Mean 9.2 ± 4.4 Range 1.42–19	SS: <i>n</i> =212 SC: <i>n</i> =3 Sβ: <i>n</i> =8 SDPunjab: <i>n</i> =2	VOC, ACS, low Hb Stroke Abnormal transcranial doppler Cardiac ischaemia	No Max 40	Mean 21.2 ± 6.1 Median 20 Range 6.25–42
31	United States “HUSOFT extension”	21	Median 3.4 Range 2.6–4.4	SS: <i>n</i> =20 Sβ ⁰ : <i>n</i> =1	Not on the basis of the disease severity	30	Mean 30 ± 1.2

Altura et al.²⁴ with escalating doses of HU every six months over a period of 18 months (maximum dose: 30 mg/kg/day). Finally, the doses used in the French and Belgian studies are close to the MTD.

The mean duration of treatment ranged between 10¹⁴ and 47 months²⁹ (range: 3 to 101 months). Several studies involved longer periods of treatment²⁹⁻³¹. In Ferster's study, 39 of the 127 patients have been treated for five years or more²⁹. In the French study 75 of the 225 children have been treated for more than five years and 10 for more than 10 years³⁰. In the "HUSOFT extension study", 11 out of 21 patients were treated for a total of six years³¹.

Biological effects

Despite the difference in the study designs, results were rather concordant. HU induced a rise in HbF levels in almost all children (Figure 1A). Only seven children were considered as non responders^{8,11,12,24,25}. However, a large inter-individual variability was observed, both in the rate of HbF increase and in the maximal HbF (HbF max) level achieved. The relative increase over the initial values varied from 1.5 to 16 fold^{8-13,15,16,18,19,21,22,24-29} with a HbF max greater than 35% in a few children^{9,11,12,25}.

Significant HbF max is *usually* reached after six months treatment. HbF max was reached at 24 months in one patient¹²; i.e. HbF value at six months is *not* predictive of HbF max. After reaching its maximum, HbF generally remained sustained at this level or at a level just slightly lower. In one study, the HbF max was reached after nine months¹³. Most of the young patients treated for two years by Wang et al.²³ had a significant upward trend in Hb and HbF (20.3 ± 4.9 %) compared with the pre-treatment values and the expected age-related levels (10.9 ± 7.9 %) documented in untreated SCA infants. Ware et al.²⁶ found that baseline HbF values and Hb concentration, MTD dose and compliance to treatment were significantly associated with a higher HbF level at MTD.

The treatment-associated changes in laboratory variables were also highly predictive of the HbF response: greater positive changes in Hb concentration and mean corpuscular volume (MCV) as well as greater negative changes in reticulocyte and white blood cell count were associated with a higher HbF level at MTD suggesting that HU dose escalation to mild myelosuppression is desirable for Hb max response²⁶. Steinberg et al.⁷ showed that adult patients with low reticulocyte counts and low Hb levels also had lower HbF levels and received lower doses of HU when treated in

the Multi-Center Study of Hydroxyurea (MSH) randomised trial⁶, suggesting that these patients had more severe disease and perhaps reduced marrow reserve unable to tolerate sufficient HU treatment to increase HbF levels.

Among the other laboratory values, the MCV and total Hb (Figures 1B and 1C) were consistently increased when compared with the pre-treatment values in almost all studies^{8-13,15-19,21,24,27-29}. These values were also significantly increased in very young children when compared to the expected age-related levels^{23,31}. In two studies^{22,27}, concerning S/C children, the MCV increased significantly without change in Hb concentration but the pre-treatment Hb values were already relatively high.

A significant decrease in the reticulocyte count was reported in six studies^{9-12,15,18,27} while this decrease was not significant in two other studies^{8,22} (Figure 1D). Reticulocyte count was also significantly lower when compared to the expected age-related levels³¹.

The number of white blood cells and neutrophils (Figure 1E) decreased consistently in 12 studies^{9-12,15,16,18,19,21,22,27,29}, a decrease also observed when compared to the expected age-related values in the infants^{23,31}. A significant decrease in platelets was reported in five studies^{10,15,16,18,27} and a non significant decrease in five others^{9,11,12,19,22,23}.

Serum bilirubin concentration decreased significantly in six studies^{8,10,15,18,27,32}. HU decreases in serum bilirubin level were significantly different among the three repetition polymorphism genotypes in the uridine diphosphoglucuronate glucuronosyl-transferase 1A (UGT1A) promoter³². Children with the homozygous 6/6 genotype have a significant reduction in total bilirubin to within the normal range after 12 to 18 months of therapy, whereas heterozygous 6/7 and homozygous 7/7 children (representing approximately two thirds of African children) have a significant reduction in total bilirubin, but not to the normal range.

Clinical effects

In all the studies, the beneficial effects of HU treatment were clinically evident by a 39–68% decrease in the VOC frequency^{10,13-16,21,22,25} and in the number of admissions (about 55%)^{8,9,19,21,22,29} and admission days (37–74%)^{8-16,19,21,22,29}. A significant decrease in the ACS frequency (68–85%)^{13,15,16,21} and need for transfusion (75–90%)^{10,13-16,19,25} was also reported. In one study⁹, 16 of the 22 patients studied did not require any hospitalisation during the six-month




Figure 1 Effect of HU therapy on HbF levels (1A); total Hb (1B); MCV (1C); reticulocyte counts (1D) and neutrophils (1E)

Each pair of bars represents the value before and after treatment in different representative studies. Black bars correspond to studies in which MTD has been reached. Values are given in mean \pm SD. Figures on the top of each couple of bars are absolute differences between the mean value before and after treatment.

trial period, even when previously seriously disabled. Most investigators noted that there was no correlation between the delayed biological effect appreciated on the HbF, total Hb or even MCV values and the rapid clinical improvement with the exception of one study in which the clinical improvement was greater after one year of treatment⁸.

Cerebrovascular

Nine patients with cerebrovascular events were studied²¹ and remained free of new clinical neurological complications after a follow up of four years; some of them had received a blood transfusion during the first months after starting HU treatment. Unfortunately, it is not mentioned if a cerebral vasculopathy in these patients was documented by magnetic resonance angiography (MRA). In another study²⁹, one recurrent

stroke was observed after six years of follow up among the eight patients included for stroke. Among the other 34 patients considered at risk of primary stroke on the basis of abnormal TCD, only one presented with a cerebrovascular event (seizures). Eleven of them have been prospectively followed by TCD; the mean TCD velocities significantly decreased and two patients had TCD velocities that returned to normal value on HU. Among these 34 patients, 26 underwent magnetic resonance imaging (MRI)/MRA studies, which were interpreted as abnormal (arterial stenosis) in seven patients²⁹.

Among the 35 patients with infarctive stroke in whom HU treatment was used as an alternative to blood transfusion^{17,28}, seven (20 % or 5.7 events per 100 patient years) had neurological events considered as recurrent stroke (all infarctive events, no transient ischaemic attacks or seizures),

i.e. just slightly higher to the secondary stroke rate on chronic transfusions. Among these 35 patients, the 20 patients who overlapped HU therapy with transfusions had a lower stroke recurrence rate of 3.6 events per 100 patient years (two patients of the 20, i.e. 10 %). No data regarding TCD studies were reported by the authors. Here again, in absence of data concerning MRA studies, we do not know if the patients who experienced a recurrence of stroke had a cerebral vasculopathy. Recurrent stroke occurred in several patients who had a history of stroke²⁷.

Young children

In Wang's study²³, 21 young children (not enrolled on the basis of clinical history) completed two years of follow up at a median age of 39 months (range 30–52 months). They experienced a number of clinical events. One child died, two developed splenic sequestration, two had clinical central nervous system events and three had a total of seven episodes of ACS. Two children had invasive pneumococcal infections without neutropenia, two had a total of eight mild VOC and two had priapism. 47% had functional asplenia (scintigraphic measurement) at an age when about 80% would be expected to have it. No patient had decreased growth velocity compared with untreated age-matched control SCA patients. Therefore, for a drug exposure of two years at a median dose of 20 mg/kg/day, no prevention of severe clinical events occurred. Even though haematological responses occurred and neutropenia was observed in some children, the authors argue that their study cannot be compared to others because of its scope, the limited period of drug exposure and the use of an HU dose lower than predicted MTD. Similar results were observed in the "HUSOFT extension study"³¹.

Splenic function

In another study²⁵ aimed to evaluate the effects of HU treatment on long-term splenic function evaluated by spleen scintigraphy, this function improved in 10 patients, remained unchanged in eight and worsened in three.

Deaths

In all these studies, six children and one adult died. One aged 15 years died after three months of treatment because of an acute intracranial haemorrhage⁸. One who had a history of previous stroke died 2.5 years after inclusion from suspected intracranial haemorrhage⁹. One infant, aged 16 months, died from an acute episode of splenic sequestration after two months of treatment²³. One four-year old SS child, splenec-

tomised at the age of two years, died of pneumococcal sepsis after 3.5 years of treatment^{27,31}. One 15-year old SS child died of acute transfusion reaction after 5.4 years of treatment²⁷. One patient with previous history of splenic sequestration, 13-months old at inclusion, died during the second year of HU therapy from an episode of splenic sequestration²⁹. Additionally, one 18-year old patient, who had received HU for 11 months, died suddenly from asystole while he was hospitalised for VOC³⁰.

Short-term side effects

Haematological toxicity has been reported in the majority of studies, including cytopenia^{8,11,12,16,17,19,21,23,27,29,30}, and/or significant decrease in total white cell^{10,13,15,16,18,20,22,23,27,30,31}, platelet^{9,15,18,20,22,23,27,29-31}, and absolute reticulocyte counts^{8,11,12,18,20,27,30}. This toxicity was usually transitory, only requiring temporary dose reduction or temporary discontinuation of HU treatment^{8,11,13,15-18,20-23,27,29-31}. In one case, HU therapy was definitively interrupted after idiopathic thrombocytopenic purpura occurred¹⁴. A few cases with transient increase in transaminase activity have been reported^{11,18,19,23}, also requiring a decrease or cessation, both transitory, of HU administration. A significant increase in serum creatinine from $43 \pm 11 \mu\text{mol/l}$ to $50 \pm 14 \mu\text{mol/l}$ ($P = 0.05$) was noted in children receiving MTD of HU¹⁵. One 13-year old girl without any history of renal disease developed acute renal failure when a systemic lupus erythematosus syndrome occurred requiring haemodialysis and definitive cessation of HU treatment^{11,12,30}.

Other reported side effects included skin rash^{8,15,18,20,30}, hair loss^{10,11,15,20}, melanonychia or hyperpigmented ridges on fingernails^{11,13,20,27,33} and conjunctivitis¹⁵. It is noticeable that seven out of 50 African-American children developed hyperpigmentation on nails, palms and other skin surfaces after short term HU therapy (mean 8–12 weeks) at relatively low doses (17–25 mg/kg/day)³⁴. Nausea^{10,15,18,27} and diarrhoea¹⁸ have been occasionally reported, as have headache^{8,18,20,30} and drowsiness²⁰ at the beginning of HU treatment. Two patients had an accidental overdose of HU²³, followed by a mild transient neutropenia, HU having been withheld for 21 and 11 days respectively.

The reasons for interrupting HU therapy can be its failure^{8,10,11,13,20,21,29,30}, including the appearance of stroke^{18,19,23,30} or the necessity for a bone marrow transplant^{21,29}, bad compliance to treatment^{8,10,11,13,18,20,21,23,27,30}, pregnancy^{8,20,29,30}, side effects such as skin rash^{8,20,30}, leg ulcer^{20,30}, nausea¹⁰, neutropenia¹⁸, thrombopenia¹⁸,

idiopathic thrombocytopenic purpura¹⁴, serum alanine aminotransferase increase¹⁸, renal failure^{11,20}, leukaemia^{20,29,30}, systemic lupus syndrome diagnosed one year after the beginning of treatment²⁹, Hb level higher than 13 g/dl in a S/C patient²⁹, hypersplenism³⁰, osteonecrosis of femoral head³⁰, headache³⁰ and dizziness³⁰.

Long-term side effects

Long-term tolerance to HU therapy in terms of growth is good. There was no growth retardation in studies where growth was monitored^{8,11-13,18-20,22,23,27,31,35}. One study reported normal pubertal development⁸; however, two cases of secondary amenorrhea have been reported^{11,20}.

The risk of potential malignancy is poorly documented in paediatric studies. To date, three cases of malignant disease have been published^{20,29,30,36,37} without apparent relationship between HU treatment and malignancy. The first case concerned a 10-year old child with the SS genotype who developed acute lymphoblastic leukaemia with evidence of Philadelphia chromosome, seven weeks after the onset of HU therapy; in that case, the painful bone crises for which HU was begun may have been due to leukaemia^{20,30,36}. The second case was an acute promyelocytic leukaemia diagnosed after eight years of HU therapy in a 21-year old patient²⁹. The third case concerned an 8-year old S β ⁰ thal child who developed Hodgkin's disease six months after initiation of HU treatment for painful crises³⁷. There was no increase in the number of acquired somatic DNA mutations after HU treatment for either eight years²⁷ or 30 months³⁸ in the two studies which looked for this. However, DNA damage in blood leukocytes of 28 SCA individuals treated with HU was significantly higher than in 28 controls³⁹; DNA damage was positively correlated with the mean HU dose (> 20 mg/kg/day) and with the duration of treatment (\geq 42 months).

A reversible azoospermia has been reported in a SS patient in whom HU therapy was initiated at the age of 17 years⁴⁰. While spermatid analysis was normal before therapy, azoospermia was discovered six months later leading to interrupt HU. A reduced number of spermatozoa with reduced motility were present 10 months after cessation of HU therapy, a complication otherwise well known in untreated patients with SCA. A retrospective study⁴¹ of four adult men showed that HU generally reduces sperm counts and motility; cessation of HU in three cases resulted in recovery of spermatogenesis in one case, however sperm morphology and motility remained impaired in the two other cases.

Specific problems to childhood and unsolved problems

Studies concerning HU therapy in children show that this drug seems to prevent VOC and their consequences. However, several points specific to childhood remain to be discussed.

Compliance

HU compliance has not been evaluated in all studies; it was precisely assessed in the "HUG-KIDS study" concerning 84 children¹⁸ among them 74 % were compliant. Three other studies found that between 7.5 and 14% of children discontinued HU therapy because of poor compliance^{27,28,30}.

Age of initiation of therapy

One question concerns the age at which treatment should be initiated to prevent tissue damage while cytotoxicity of HU could affect the development of brain cells. Only a few studies have involved children aged less than five years^{19,20,29} or less than two years^{23,29,31}. With a mean follow up of three years, no side effect has been observed, particularly concerning growth. However, administration of high doses of HU to young mice has been shown to affect brain development and behaviour⁴². For this reason and also to avoid adverse effect of HU upon growth, to date not proven, it seems reasonable not to initiate HU therapy before the age of two years.

Splenic function

Therapy in children aged less than 5 years may delay functional asplenia and, despite the risk of severe infections, might prolong the period of risk for acute splenic sequestration^{23,31}. A retrospective study⁴³ suggests that HU possibly preserves spleen function in SCA children, and can even result in recovery of splenic function.

Cerebrovascular

It has been postulated that HU could be effective as stroke prophylaxis in reducing adhesion molecule expression on sickle erythrocytes and in increasing steady-state Hb⁴⁴. HU was used in 35 children with SCA and stroke in whom transfusions given to prevent stroke occurrence were discontinued because of antibodies, recurrent stroke despite transfusions, iron overload, non compliance and/or desferrioxamine allergy²⁸. Seven patients (20% or 5.7 events per 100 patient years) had neurological events considered to be recurrent strokes²⁸. When HU therapy overlapped with transfusions, the recurrence rate

was lower (3.6 events per 100 patient year) and comparable with the published stroke recurrence rates for children with SCA receiving transfusion prophylaxis against secondary stroke (2.2 events per 100 patient years)^{45,46}. The secondary stroke rates from these three articles^{28,45,46} are not, however, directly comparable⁴⁷.

These results suggest that HU could be effective for preventing secondary stroke in children with SCA, but when performed with an overlap period allowing escalation of HU to MTD while still receiving transfusions. Other studies, particularly large clinical trials, are necessary in order to answer the question whether HU is effective for prevention of stroke in comparison to the effect of transfusion prophylaxis well documented by large studies. The Stroke with Transfusions Changing to Hydroxyurea (SWITCH) Trial is a randomised phase 3 multicentre study which began enrolment in 2006 and is ongoing⁴⁸. Furthermore, no controlled study has been made in those children considered at risk because of abnormal results on TCD. In a French study⁴⁹, 10 patients with abnormal TCD, whose velocities normalised on transfusion, were switched to treatment with HU. Four patients reverted to abnormal TCD and were placed back on transfusion, but six continued to receive HU after a median of 4.4 years of follow up. A recent study⁵⁰ showed that 24 HU-treated children experienced statistically significant decreases in TCD velocities compared to age-matched controls, which was not a consequence of changes in haematological parameters. A prospective phase 2 trial⁵¹ included 37 children with pre-treatment increased TCD velocities. TCD velocities were then measured at MTD and one year later. At MTD, significant decreases were observed and the magnitude of TCD velocity decline was significantly correlated with the maximal baseline TCD value. TCD changes were sustained at follow up. A recent retrospective study summarising the Belgian experience⁵² found that the significant increase with age of the TCD velocities did not appear in the patients treated with HU, and that in the 21 patients with an abnormal first TCD, the velocities decreased to the normal range in eight of them. Furthermore, children with highest baseline TCD velocities had the greatest treatment-related decreases.

To date, chronic transfusion to maintain HbS below 30% in high-risk group remains the only proven prevention strategy for stroke in SCA⁵³, but the data indicate that HU might be an alternative to chronic transfusion for primary stroke prevention in children at risk for stroke on the basis of abnormal TCD⁵⁴.

Limitations of clinical trials

After publication of the MSH⁶ and the Stroke Prevention (STOP)⁵⁵ trials, use of HU and TCD assessment has drifted towards a standard practice without evidence of therapeutic efficacy among groups that were excluded from the trials⁵⁶. Therefore, despite the potential differences in dosing, safety, and efficacy between drug trials in adults when compared with children, pediatricians are often forced to rely on data from studies performed in adults to make treatment decisions in children⁵⁶. It is also difficult to extend the results of the MSH and the STOP trials to patients with haemoglobin SC^{56,57}, since both trials have limited the inclusions to individuals with haemoglobin SS (and S β^0 -thalassaemia in the STOP trial).

Predictive response to HU therapy

Children seem to be better responders to HU therapy than adults, although the clinical and haematological response is variable⁵⁸. As already quoted, efficacy of treatment is not predicted from the initial HbF level¹². In fact, clinical response to HU in children is rapid and constant while resultant HbF increase is late and variable from one patient to another in level (a few to 30%) and in time (a few weeks to more than one year)^{12,59}. Furthermore, the beneficial efficacy of HU upon clinical manifestations quickly decreases when discontinued while HbF levels remain high. A recent study⁶⁰ showed that some genetic determinants were associated with the HbF response to HU. Thus, it appears clear that induction of HbF is unlikely to explain all the clinical effects of HU. Adhesion and/or other mechanisms seems to be implicated in the individual response⁶¹.

Mode of action of HU

HU, also named hydroxycarbamide, is a hydroxylated derivative of urea, $\text{H}_2\text{N}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{OH}$. It is a cytotoxic agent used since the sixties for treating malignant diseases (polycythemia vera, head and neck cancers, chronic granulocytic leukaemia), cyanotic congenital heart diseases^{62,63} and even more recently psoriasis and HIV infection in association with nucleoside analogues⁶⁴. HU is a freely water-soluble molecule with a molecular weight of 76. Given orally, it crosses the intestinal wall by passive diffusion and its maximal plasma concentration is rapidly reached ($T_{\text{max}} = 1.22$ hours); its oral bioavailability is nearly complete⁶⁴. It is rapidly metabolised and converted into urea in the liver. Elimination of HU and its metabolites is mainly renal.

HU crosses the meningeal barrier, placental tissue and is present in maternal milk. Urinary HU was present for at least 12 hours following HU ingestion, but marked differences in urinary HU concentrations were noted⁶⁵. There was a positive relationship between plasma HU concentrations and time elapsed between oral HU intake and sampling in 37 adults⁶⁶. Little is known about the pharmacokinetics of HU in children with SCA. A recent study⁶⁷ showed that pharmacokinetic parameters were not significantly different between adults and children, but considerable inter-individual variability was noted suggesting that differences in pharmacokinetics might contribute to the differences in clinical responses.

HU inhibits the ribonucleotide reductase that catalyses conversion of ribonucleotides into deoxyribonucleotides. Consequently, HU inhibits DNA synthesis and arrests cells in S-phase. As already mentioned, the efficacy of HU in SCA was initially attributed to pharmacological stimulation of HbF⁶⁸. The cyto-reductive effect of HU was thought to result in differentiation of erythroid precursors with a relative increase of cells with high level of HbF. In fact, absence of complications during the first months of life seemed to be correlated with elevated HbF levels while secondary occurrence of painful crisis appeared to be coincidental with physiological decrease in HbF. Moreover, patients with low HbF level frequently develop a more severe disease⁶⁹ and have a reduced life expectancy⁷⁰, and it was even suggested that HbF level should be considered an important factor in selecting children for high-risk interventions such as bone marrow transplantation and long term treatment with agents that stimulate the production of HbF⁷⁰. HbF within the cell interferes with HbS polymerisation and sickling. However, HU therapy was often associated with clinical improvement before any observable rise in HbF and the achieved level of HbF did not regularly predict response^{6,12,71}. In addition, improvement vanishes rapidly if HU is discontinued, even if the patient still maintains a high level of HbF.

These data indicate that HbS polymerisation and sickling are not the only phenomenon influenced by HU. Indeed, new data suggest that HU may act by additional mechanisms affecting other aspects of the pathophysiology of SCA. Reduction by HU of adhesion molecule expression on sickle red cells and reticulocytes to endothelial cells⁷², and to the subendothelial matrix proteins thrombospondin and laminin⁷³ can play a role as does a decrease in the percentage of reticulocytes expressing VLA-4 and CD36⁷⁴ and soluble VCAM-1 molecules⁷⁵. HU significantly reduced sickle red cell adhesion to fibronectin, and reticulocytes from patients

on HU had significantly lower CD36 and CD49d (α -subunit of VLA-4) surface expressions, as well as significantly lower CD36, CD49d and CD29 (β -subunit of the VLA-4) gene expressions⁷⁶. It has been recently shown that HU decreases the VCAM-1 expression and the ET-1 peptide release from endothelial cells in culture^{77,78} and the plasma ET-1 level in children with SCA⁷⁹. Finally, our group⁸⁰ recently showed that on reticulocytes from SCA children treated with HU, expression of CD36, VLA-4 and ICAM-4 (to a lower extent) was decreased, but surprisingly Lu/BCAM expression (also CD47 and CD147 to a lower extent) was significantly increased. Alterations of adhesion receptor levels could be recapitulated in two-phase liquid cultures of erythroid progenitors from controls and the symptomatic patients grown in the absence or presence of HU.

These results suggest that in addition to red cells, endothelial cells are other cellular targets for HU⁸¹. A variety of alterations in sickle erythrocytes could result from HU administration^{71,82}. This drug could also exert its impact through myelosuppression^{71,82} with reduction in neutrophil counts and through reduction in neutrophil activation⁸³. Finally, it has recently been suggested that the action of HU on gene expression, at the molecular level, might result from its capacity to act as a nitric oxide (NO) donor and thereby to activate the NO-mediated soluble guanylate cyclase (sGC) and cGMP signalling pathway⁸⁴⁻⁸⁶. Therefore, NO release^{71,82} might also lead to vasodilatation.

Thus, clearly HU has pleiotropic effects on various aspects of SCA. It is a very effective drug, but potential long-term adverse effects are still uncertain. A better understanding of its mode of action is likely to provide important new data crucial for the identification of new therapeutic targets and an in-depth understanding of SCA pathophysiology. This is crucial if HU is to be used early on in SCA patients and for a life-long treatment.

Conclusion

HU has become an essential drug for the management of severe cases of SCA in children. According to the data reported above and in accordance with market authorisations by the EMEA and FDA (Table 2), it seems reasonable; (1) not to initiate HU therapy before the age of two years; (2) to start the treatment at the initial dose of 15 mg/kg/day, then to increase by 5 mg/kg until the optimal dose which is the dose leading to a clinical effect and avoiding bone marrow toxicity (remaining below 35 mg/kg/day); (3) to start HU in cases of severe vaso-occlusive disease (usually three or more severe VOCs during the last year

Table 2 Recommendations for use of hydroxyurea (HU) = hydroxycarbamide
Note that FDA recommendation apply to adult patients only

	EMA (European Medicines Agency)	FDA (Food and Drug Administration)
Name of the medicinal product	SIKLOS®	DROXIA®
Date of issue of marketing authorisation	29 June 2007	25 February 1998
Orphan medicinal product designation date	9 July 2003	
Therapeutic indication	Prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle cell syndrome	To reduce the frequency of painful crises and to reduce the need for blood transfusion in adult patients with sickle cell anaemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months)
Oral use as	1000 mg breakable tablets (into four equal parts)	200, 300, 400 mg capsules
Recommendation for administration	Initiation by a physician experienced in the management of sickle cell syndrome	
Starting dose		15 mg/kg/day as single dose
Usual dose	15–30 mg/kg/day If necessary, maximum dose of 35 mg/kg/day under close haematologic monitoring Stop treatment if no response (35 mg/kg/day over 3–6 months) Reduced dose if mild renal impairment	If blood counts are in an acceptable range : – neutrophil levels $\geq 2500/\text{mm}^3$ – platelets $\geq 95000/\text{mm}^3$ – hemoglobin (Hb) $> 5.3 \text{ g/dl}$ – reticulocytes $\geq 95000/\text{mm}^3$ when Hb $< 9 \text{ g/dl}$ the dose may be increased by 5 mg/kg/day every 12 weeks until a maximum tolerated dose (the highest dose that does not produce toxic blood counts over 24 consecutive weeks), or 35 mg/kg/day Initial dose reduced if renal impairment Discontinued until haematological recovery (then be reinstituted at a reduced dose) if : – neutrophil levels $< 2000 /\text{mm}^3$ – platelets $< 80000 /\text{mm}^3$ – haemoglobin $< 4.5 \text{ g/dL}$ – reticulocytes $< 80000 /\text{mm}^3$ when haemoglobin $< 9 \text{ g/dL}$
Checking before and during treatment	– Blood cell counts every 2 weeks for the first 2 months (and if $> 35 \text{ mg/kg/day}$), then every 2 months – Renal and liver functions	– Blood counts prior to, and every 2 weeks during the duration of therapy – Renal and liver functions
Cautions	– Not recommended for children aged below 2 years – Continuous follow-up of the growth of treated children is recommended – Use of effective contraception is strongly recommended for women; if becomes pregnant while taking HU should be advised of the potential risk to the fetus – Patients with leg ulcer	– Safety and effectiveness in paediatric patients have not been established – Women of childbearing potential should be advised to avoid becoming pregnant; if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus – Discontinue nursing, or discontinue Droxia if breast-feeding
Contraindications	– Hypersensitive to hydroxycarbamide or to any of the excipients – Severe renal or liver impairment – Toxic ranges of myelosuppression – Breast-feeding must be discontinued while taking Siklos	– Previous hypersensitivity to hydroxyurea or any other component of its formulation
Risk management plan	– Cohort follow-up : 2000 patients up to 8 years recruitment, total duration 10 years – Information kit for physicians and patients	– Information kit for patients
Reference	http://emea.europa.eu/humandocs/Humans/EPAR/siklos/siklos.htm	http://www.fda.gov/cder/foi/nda/2003/16-295S036_Droxia_Prntlbl.pdf

and/or two or more ACSs requiring hospitalisation during the last or the two last years, and/or priapism); and (4) that the initial prescription is made under the guidance of the sickle cell centre, and needs to take into account, and to carefully monitor the potential haematological, liver and renal toxicities.

In addition, we can suggest that: (5) HU could be used also in cases of severe anaemia with Hb

level less than 7.0 g/dl, and/or as an alternative to chronic transfusion for primary stroke prevention in children at risk for stroke on the basis of abnormal TCD; (6) we must also be careful of the possibility of prolonging the period of risk for acute splenic sequestration; and finally (7) we must inform the parents about uncertainties concerning long-term effect on fertility in young boys, and/or offer storage of frozen sperm to adults.

References

1. Herrick J. Peculiar elongated and sickle-shape red blood corpuscles in a case of severe anemia. *Arch Intern Med* 1910;6:517-521.
2. Pauling L, Itano HA et al. Sickle cell anemia a molecular disease. *Science* 1949;110:543-548.
3. Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. *Science* 1987;237:500-506.
4. Hebbel RP, Yamada O, Moldow CF et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. *J Clin Invest* 1980;65:154-160.
5. Johnson C, Telen MJ. Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. *Haematologica* 2008;93:481-485.
6. Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med* 1995;332:1317-1322.
7. Steinberg MH, Barton F, Castro O et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *Jama* 2003;289:1645-1651.
8. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. *J Pediatr* 1996;128:820-828.
9. Ferster A, Vermynen C, Cornu G et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. *Blood* 1996;88:1960-1964.
10. Jayabose S, Tugal O, Sandoval C et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. *J Pediatr* 1996;129:559-565.
11. de Montalembert M, Belloy M, Bernaudin F et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. *J Pediatr Hematol Oncol* 1997;19:313-318.
12. Maier-Redelsperger M, de Montalembert M, Flahault A et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. *Blood* 1998;91:4472-4479.
13. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. *Semin Hematol* 1997;34:42-47.
14. Oury AP, Hoyoux C, Dresse ME, Chantraine JM. Sickle cell anemia in children: value of hydroxyurea in severe forms. *Arch Pediatr* 1997;4:839-844.
15. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. *J Pediatr Hematol Oncol* 1998;20:26-31.
16. Koren A, Segal-Kupershmit D, Zalman L et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. *Pediatr Hematol Oncol* 1999;16:221-232.
17. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. *Blood* 1999;94:3022-3026.
18. Kinney TR, Helms RW, O'Branski EE et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. *Blood* 1999;94:1550-1554.
19. Hoppe C, Vichinsky E, Quirolo K et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. *J Pediatr Hematol Oncol* 2000;22:330-334.
20. de Montalembert M, Begue P, Bernaudin F et al. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. *Arch Dis Child* 1999;81:437-439.
21. Ferster A, Tahriri P, Vermynen C et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. *Blood* 2001;97:3628-3632.
22. Miller MK, Zimmerman SA, Schultz WH, Ware RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. *J Pediatr Hematol Oncol* 2001;23:306-308.
23. Wang WC, Wynn LW, Rogers ZR et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. *J Pediatr* 2001;139:790-796.
24. Altura RA, Wang WC, Wynn L, Altura BM, Altura BT. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia. *J Pediatr* 2002;140:565-569.
25. Santos A, Pinheiro V, Anjos C et al. Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. *Eur J Nucl Med Mol Imaging* 2002;29:536-541.
26. Ware RE, Eggleston B, Redding-Lallinger R et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. *Blood* 2002;99:10-14.
27. Zimmerman SA, Schultz WH, Davis JS et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. *Blood* 2004;103:2039-2045.
28. Ware RE, Zimmerman SA, Sylvestre PB et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. *J Pediatr* 2004;145:346-352.
29. Gulbis B, Haberman D, Dufour D et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. *Blood* 2005;105:2685-2690.
30. de Montalembert M, Brousse V, Elie C et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. *Haematologica* 2006;91:125-128.
31. Hankins JS, Ware RE, Rogers ZR et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. *Blood* 2005;106:2269-2275.
32. Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. *J Lab Clin Med* 2003;141:279-282.
33. Ceulen RP, Frank J, Poblete-Gutierrez P. Nail pigmentation due to hydroxycarbamide. *Int J Dermatol* 2007;46:13-15.
34. O'Branski E E, Ware RE, Prose NS, Kinney TR. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. *J Am Acad Dermatol* 2001;44:859-861.
35. Wang WC, Helms RW, Lynn HS et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. *J Pediatr* 2002;140:225-229.
36. de Montalembert M and Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? *Blood* 2001;98:2878-2879.

37. Moschovi M, Psychou F, Menegas D et al. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. *Pediatr Hematol Oncol* 2001;18: 371-376.
38. Hanft VN, Fruchtmann SR, Pickens CV et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. *Blood* 2000;95:3589-3593.
39. Friedrich JR, Pra D, Maluf SW et al. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. *Mutat Res* 2008;649:213-220.
40. Garozzo G, Disca S, Fidone C, Bonomo P. Azoospermia in a patient with sickle cell disease treated with hydroxyurea. *Haematologica* 2000;85:1216-1218.
41. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. *Intern Med J* 2007;37:190-192.
42. Horiuchi K, Golden J, Das S. Adverse effects of hydroxyurea on growth and development of young mice. *Blood* 1998;92:160a.
43. Hankins JS, Helton KJ, McCarville MB et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. *Pediatr Blood Cancer* 2008;50:293-297.
44. Wang WC. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. *Curr Opin Hematol* 2007;14:191-197.
45. Pegelow CH, Adams RJ, McKie V et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. *J Pediatr* 1995;126:896-899.
46. Scothorn DJ, Price C, Schwartz D et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. *J Pediatr* 2002;140: 348-354.
47. DeBaun MR. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia. *J Pediatr* 2005;147:560-561.
48. National Heart, Lung, and Blood Institute (NHLBI). Stroke with transfusions changing to hydroxyurea (SWITCH) (2006). <http://clinicaltrials.gov/show/nct00122980>.
49. Bernaudin F, Verlhac S, Coic L et al. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. *Pediatr Radiol* 2005;35:242-248.
50. Kratovil T, Bulas D, Driscoll MC et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. *Pediatr Blood Cancer* 2006;47:894-900.
51. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. *Blood* 2007;110:1043-1047.
52. Lefevre N, Dufour D, Gulbis B et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. *Blood* 2008;111:963-964.
53. Mehta SH and Adams RJ. Treatment and prevention of stroke in children with sickle cell disease. *Curr Treat Options Neurol* 2006;8:503-512.
54. Ware RE. TCD response to hydroxyurea therapy. *Blood* 2008;111:964.
55. Adams RJ, McKie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med* 1998;339:5-11.
56. Debaun MR, Field JJ. Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) Trial and the Stroke Prevention (STOP) Trial. *Hematology Am Soc Hematol Educ Program* 2007;2007:482-488.
57. Ohene-Frempong K, Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next? *Semin Hematol* 1997;34:30-41.
58. Amrolia PJ, Almeida A, Halsey C, Roberts IA, Davies SC. Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options. *Br J Haematol* 2003;120:725-736.
59. Maier-Redelsperger M, Labie D, Elion J. Long-term hydroxyurea treatment in young sickle cell patients. *Curr Opin Hematol* 1999;6:115-120.
60. Ma Q, Wyszynski DE, Farrell JJ et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. *Pharmacogenomics J* 2007;7:386-394.
61. Weiner DL, Brugnara C. Hydroxyurea and sickle cell disease: a chance for every patient. *Jama* 2003;289:1692-1694.
62. Cornu P. Long-term hematological management of cyanotic congenital heart diseases. *Arch Mal Coeur Vaiss* 1994;87:1413-1420.
63. Triadou P, Maier-Redelsperger M, Krishnamoorthy R et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. *Nouv Rev Fr Hematol* 1994;36:367-372.
64. Stevens MR. Hydroxyurea: an overview. *J Biol Regul Homeost Agents* 1999;13:172-175.
65. Dalton RN, Turner C, Dick M et al. The measurement of urinary hydroxyurea in sickle cell anaemia. *Br J Haematol* 2005;130:138-144.
66. Bachir D, Hulin A, Huet E et al. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. *Hemoglobin* 2007;31:417-425.
67. de Montalembert M, Bachir D, Hulin A et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. *Haematologica* 2006;91:1685-1688.
68. Charache S, Dover GJ, Moore RD et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. *Blood* 1992;79:2555-2565.
69. Platt OS, Thorington BD, Brambilla DJ et al. Pain in sickle cell disease. Rates and risk factors. *N Engl J Med* 1991;325:11-16.
70. Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med* 1994;330: 1639-1644.
71. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. *Br J Haematol* 2003;120: 177-186.
72. Bridges KR, Barabino GD, Brugnara C et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. *Blood* 1996;88:4701-4710.
73. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. *Br J Haematol* 2000;109:322-327.
74. Styles LA, Lubin B, Vichinsky E et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. *Blood* 1997;89:2554-2559.
75. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. *Acta Haematol* 1999;102:31-37.
76. Gambero S, Canalli AA, Traina F et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. *Eur J Haematol* 2007;78:144-151.

77. Brun M, Bourdoulous S, Couraud PO et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. *Pharmacogenomics J* 2003;3:215-226.
78. Lapoumeroulie C, Brun M, Odievre MH, Krishnamoorthy R. Endothelial cells are targets for hydroxyurea: Relevance to the current therapeutic strategy in sickle cell disease. In: J.L.a.M.-L. Wong. *The Pharmacogenomics Journal*. Weinheim(Germany): Wiley-Vch, 2002:235-249.
79. Lapoumeroulie C, Benkerrou M, Odievre MH et al. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. *Haematologica* 2005;90:401-403.
80. Odievre MH, Bony V, Benkerrou M et al. Modulation of erythroid adhesion receptors expression by hydroxyurea in children with sickle cell disease. *Haematologica* 2008;93:502-510.
81. Elion JE, Brun M, Odievre MH, Lapoumeroulie CL, Krishnamoorthy R. Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. *Hematol J* 2004;5:S195-S198.
82. Davies SC, Gilmore A. The role of hydroxyurea in the management of sickle cell disease. *Blood Rev* 2003;17:99-109.
83. Benkerrou M, Delarche C, Brahimi L et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. *Blood* 2002;99:2297-2303.
84. Cokic VP, Smith RD, Beleslin-Cokic BB et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. *J Clin Invest* 2003;111:231-239.
85. Cokic VP, Beleslin-Cokic BB, Tomic M et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. *Blood* 2006;108:184-191.
86. Cokic VP, Andric SA, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. *Blood* 2008;111:1117-1123.

CrossRefs are available in the online published version of this paper:

<http://www.librapharm.com>

Paper PPDT-0209_3, *Accepted for publication:* 28 April 2008

Published Online: 27 May 2008

doi:10.1185/146300908X292060